Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $2.40-2.50 for the period, compared to the consensus estimate of $2.45. The company issued revenue guidance of $16.10-16.50 billion, compared to the consensus revenue estimate of $16.27 billion. Teva Pharmaceutical Industries also updated its FY 2024 guidance to 2.400-2.500 EPS.
Teva Pharmaceutical Industries Stock Performance
Shares of NYSE TEVA traded down $1.34 during mid-day trading on Wednesday, reaching $17.43. The company's stock had a trading volume of 18,205,340 shares, compared to its average volume of 9,296,823. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a fifty day moving average of $18.03 and a two-hundred day moving average of $17.06. Teva Pharmaceutical Industries has a 52 week low of $8.55 and a 52 week high of $19.31.
Analyst Upgrades and Downgrades
TEVA has been the subject of a number of recent analyst reports. Argus raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Barclays boosted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. Finally, UBS Group upped their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $19.67.
View Our Latest Research Report on TEVA
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
